Corrigendum: 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) [Ann Oncol, 28, 1, (2016), (16-33)] doi: 10.1093/annonc/mdw544;3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Annals of Oncology

Volumn 28, Issue 1, 2017, Pages 16-33

  Cardoso, F ^a   Costa, A ^b,c   Senkus, E ^d   Aapro, M ^e   Andre F ^f   Barrios, C H ^g   Bergh, J ^h   Bhattacharyya, G ⁱ   Biganzoli, L ^j   Cardoso, M J ^a   Carey, L ^k   Corneliussen James, D ^l   Curigliano, G ^m   Dieras, V ⁿ   El Saghir, N ^o   Eniu, A ^p   Fallowfield, L ^q   Fenech, D ^r   Francis, P ^s   Gelmon, K ^t   Gennari, A ^u   Harbeck, N ^v   Hudis, C ^w   Kaufman, B ^x   Krop, I ^y   Mayer, M ^z   Meijer, H ^aa   Mertz, S ^ab   Ohno, S ^ac   Pagani, O ^ad   Papadopoulos, E ^ae   Peccatori, F ^b,af   Penault Llorca, F ^ag   Piccart, M J ^ah   Pierga, J Y ^ai   Rugo, H ^aj   Shockney, L ^ak   Sledge, G ^al   Swain, S ^am   Thomssen, C ^an   Tutt, A ^ao   Vorobiof, D ^ap   Xu, B ^aq   Norton, L ^w   Winer, E ^y   more..

^a CHAMPALIMAUD CLINICAL CENTER   (Portugal)

^b EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^c European School of Oncology   (Sweden)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e Masaryk Oncologic Institute   (Czech Republic)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ FORTIS HOSPITAL   (India)

^j Hospital of Prato   (Italy)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l METAvivor Research and Support Inc   (United States)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁿ INSTITUT CURIE   (France)

^o AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^p Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^q UNIVERSITY OF SUSSEX   (United Kingdom)

^r Europa Donna Malta   (Malta)

^s PETER MACCALLUM CANCER CENTRE   (Australia)

^t BRITISH COLUMBIA CANCER AGENCY   (Canada)

^u GALLIERA HOSPITAL   (Italy)

^v UNIVERSITY OF MUNICH   (Germany)

^w MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^x SHEBA MEDICAL CENTER   (Israel)

^y DANA FARBER CANCER INSTITUTE   (United States)

^z Advanced Breast Cancerorg   (United States)

^aa RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^ab Metastatic Breast Cancer Network US   (United States)

^ac CANCER INSTITUTE HOSPITAL   (Japan)

^ad ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^ae EUROPA DONNA Cyprus   (Cyprus)

^af Université Libre de Bruxelles ^*  (Switzerland)

^ag Jean Perrin Comprehensive Cancer Centre   (France)

^ah JULES BORDET INSTITUTE   (Belgium)

^ai UNIVERSITÉ PARIS DESCARTES   (France)

^aj UNIVERSITY OF CALIFORNIA   (United States)

^ak The Johns Hopkins Avon Foundation Breast Center   (United States)

^al INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^am GEORGETOWN UNIVERSITY   (United States)

^an MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^ao GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^ap Sandton Oncology Centre   (South Africa)

^aq PEKING UNION MEDICAL COLLEGE   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; ESTRADIOL; ESTROGEN RECEPTOR; EVEROLIMUS; FULVESTRANT; GEMCITABINE; LAPATINIB; MEGESTROL ACETATE; PALBOCICLIB; PERTUZUMAB; TAMOXIFEN; TAXANE DERIVATIVE; TUMOR MARKER; VINORELBINE TARTRATE;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; LIVER METASTASIS; MALIGNANT PLEURA EFFUSION; MASTECTOMY; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PALLIATIVE THERAPY; PATIENT PREFERENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR ABLATION; BREAST TUMOR; FEMALE; MALE; OBSERVATIONAL STUDY; PATHOLOGY;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; HUMANS; MALE; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85015780252     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx036     Document Type: Erratum

References (65)

1. Cardoso F, Costa A, Norton L et al. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Simultaneous publication in The Breast 2014, 23: 489-502; http://dx.doi. org/10.1016/j.breast.2014.08.009) and Annals of Oncology (Ann Oncol 2014; 25: 1871-1888; doi:10.1093/annonc/mdu385).
2. Global Status of Advanced/Metastatic Breast Cancer 2005-2015 Decade Report. www.breastcancervision.com and www.abc-lisbon.org (27 October 2016, date last accessed).
3. Howlader N, Noone AM, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016 (updated September 12 2016, 27 October 2016, date last accessed).
4. Sundquist M, Eriksson Z, Tejler G, Brudin L. Trends in survival in metastatic breast. Cancer Eur J Cancer 2010; 8(3): 191. Abstract 453.
5. Kobayashi K, Ito Y, Matsuura M et al. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today 2016; 46: 821-826.
6. Chia SK, Speers CH, D'yachkova Y et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110: 973-979.
7. Guyatt G, Gutterman D, Baumann MH et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 2006; 129: 174-181.
8. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology 2015; 26: 1547-1573.
9. Schnipper LE, Davidson NE, Wollins DS et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015; 33: 2563-2577.
10. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for advanced breast cancer (ABC1). The Breast 2012; 21: 242-252.
11. Key components of Patient Centered Care, adapted from Levit L et al. Delivering high-quality cancer care: charting a new course for a system in crisis. National Academy of Science: Institute of Medicine, The National Academies, 2013; 20, 1. 3 p.3.4-3.7.
12. Cardoso F, Harbeck N, Mertz S, Fenech D. Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: results from the count us, know us, join us and here & now surveys. The Breast 2016; 28: 5-12.
13. Karlsson E, Appelgren J, Solterbeck A et al. Breast cancer during followup and progression-a population based cohort on new cancers and changed biology. Eur J Cancer 2014; 50: 2916-2924.
14. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010; 12: R92.
15. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 587-592.
16. Penault-Llorca F, Coudry RA, Hanna WM et al. Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. Breast 2013; 22: 200-202.
17. Schrijver WA, van der Groep P, Hoefnagel LD et al. Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Mod Pathol 2016; doi:10.1038/modpathol.2016.116.
18. André F, Bachelot T, Commo F et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014; 15: 267-274.
19. Badwe R, Hawaldar R, Nair N et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an openlabel randomised controlled trial. Lancet Oncol 2015; 16: 1380-1388.
20. Soran A, Ozmen V, Ozbas S et al. A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). J Clin Oncol 2016; 34(suppl): abstr 1005.
21. Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial surgery and survival in stage IV breast cancer in the United States, 1988-2011. JAMA Surg 2016; 151: 424-431.
22. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
23. Swain SM, Kim SB, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-471.
24. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791.
25. Krop IE, Kim SB, González-Martín A et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 1: 689-699.
26. Ellis P, Barrios C, EiermannW et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study. J Clin Oncol 2015; 33(suppl): abstr 507.
27. Urruticoechea A, Rizwanullah M, Im SA et al. PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. J Clin Oncol 2016; 34(15_suppl): abstr. 504.
28. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptorpositive metastatic breast cancer: results from the randomized phase III TAnDEMstudy. J Clin Oncol 2009; 27: 5529-5537.
29. von Minckwitz G, du Bois A, SchmidtM et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/breast international group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
30. Rayson D, Lutes S, Walsh G et al. Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on firstline therapy predicts overall survival impact. Breast J 2014; 20: 408-413.
31. Tripathy D, Rugo HS, Kaufman PA et al. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer 2014; 14: 307.
32. Andersson M, Lidbrink E, Bjerre K et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29: 264-271.
33. Burstein HJ, Keshaviah A, Baron AD et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110: 965-972.
34. Smyth LM, Iyengar NM, Chen MF et al. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat 2016; 158: 91-97.
35. Andersson M, López-Vega JM, Petit T et al. The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interimanalysis. J Clin Oncol 2015; 33(15_suppl): 586.
36. Untch M, Jackisch C, Schneeweiss A et al. Nab-paclitaxel versus solventbased paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 2016; 17: 345-356.
37. Lobbezoo DJ, van Kampen RJ, Voogd AC et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol 2016; 27: 256-262.
38. Finn RS, Martin M, Rugo HS et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2-advanced breast cancer (ABC). J Clin Oncol 2016; 34 (suppl): abstr 507.
39. Weigel RJ, deConinck EC. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res 1993; 53: 3472-3474.
40. Fribbens C, O'Leary B, Kilburn L et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016; 34: 2961-2968.
41. Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of estrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25-35.
42. Turner NC, Ro J, André F et al. Palbociclib in hormone-receptorpositive advanced breast cancer. N Engl J Med 2015; 373: 209-219.
43. Harbeck N, Iyer S, Turner N et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 2016; 27: 1047-1054.
44. Piccart M, Hortobagyi GN, Campone M et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 2014; 25: 2357-2362.
45. Bachelot T, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30: 2718-2724.
46. Pritchard KI, Burris HA III, Ito Y et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013; 13: 421-432.
47. Mehta RS, Barlow WE, Albain KS et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367: 435-444.
48. Tutt A, Ellis P, Kilbum L et al. TNT: a randomized phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer. Cancer Res 2015; 75 (9 Suppl): S3-01.
49. Cortes J, Crown J, Awada A et al. Overall survival (OS) from the phase 2 study of enzalutamide, an androgen receptor (AR) signaling inhibitor, in ar+ advanced triple-negative breast cancer (aTNBC). Eur J Cancer 2015; 51(Suppl. S3): S265. abstr. 1802.
50. Bonnefoi H, Grellety T, Tredan O et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol 2016; 27: 812-818.
51. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 2011; 377: 914-923.
52. Kaufman PA, Awada A, Twelves C et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33: 594-601.
53. Munzone E, Colleoni M. Clinical overview of metronomic chemotherapy in breast cancer. Nat Rev Clin Oncol 2015; 12: 631-644.
54. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
55. Amadori D, Aglietta M, Alessi B et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 2013; 14: 663-670.
56. Hortobagyi GH, Lipton A, Chew HK et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. J Clin Oncol 2014; 32: 5s (suppl): abstr LBA9500.
57. Himelstein AL, Qin R, Novotny PJ et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol 2015; 33: (suppl): abstr 9501.
58. Jones VE, Jensen LL, McIntyre KJ et al. Evaluation of miracle mouthwash (MMW) plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: preliminary results of a randomized phase II study. 2015 San Antonio Breast Cancer Symposium; December 5-8, 2015; San Antonio, TX. Abstract P1-15-06.
59. Rugo HS, Seneviratne L, Beck JT et al. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): results of the SWISH trial. J Clin Oncol 2016; 34 (suppl); abstr 525.
60. Roila F, Molassiotis A, Herrstedt J et al. MASCC and ESMO Consensus Guidelines for the prevention of chemotherapy and radiotherapyinduced nausea and vomiting: ESMO clinical practice guidelines. Ann Oncol 2016; 27(suppl 5): v119-v133.
61. Payne C, Wiffen PJ, Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database Syst Rev 2012; 1: CD008427.
62. Berger A, Mitchell SA, Jacobsen PB, Pirl WF. Screening, evaluation and management of cancer-related fatigue: ready for implementation to practice. CA Cancer J Clin 2015; 65: 190-211.
63. Aapro M, Scotte F, Bouillet T et al. A practical approach to fatigue management in colorectal cancer. Clin Colorectal Cancer 2016; doi: 10.1016/j.clcc.2016.04.010.
64. Travier N, Velthuis MJ, Steins Bisschop CN et al. Effects of an 18-week exercise programme started early during breast cancer treatment: a randomized controlled trial. BMC Med 2015, 8: 121.
65. Koornstra RH, PetersM, Donofrio S et al. Management of fatigue in patients with cancer-a practical overview. Cancer Treat Rev 2014; 40: 791-799.